Forecast of antibiotic development in an era of increasing bacterial resistance

Journal of Pharmacy Practice

Volumn 21, Issue 5, 2008, Pages 313-318

  Eiland III, Edward H ^a   Gatlin, Derek ^a  

^a HUNTSVILLE HOSPITAL   (United States)

Author keywords

Antibacterial research and development; Antibiotic stewardship; Bacterial resistance

Indexed keywords

7 [3 (1 AMINOCYCLOPROPYL) 1 PYRROLIDINYL] 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMINOMETHYLCYCLINE; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFETAMET PIVOXIL; CEFPIROME; CEFTAROLINE; CEFTOBIPROLE; CEM 101; CEPHALOSPORIN DERIVATIVE; CETHROMYCIN; DALBAVANCIN; DC 159 A; E 1010; FAROPENEM DALOXATE; HETERODIMER; ICLAPRIM; MK 2764; NEMONOXACIN; OPT 1068; ORITAVANCIN; PRULIFLOXACIN; PTK 0796; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETAPAMULIN; RITIPENEM ACOXIL; TD 1792; TELAVANCIN; TIACUMICIN B; TOMOPENEM; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAP 8294 A2;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; FUNDING; GOVERNMENT; HUMAN; INFECTION CONTROL; INVESTMENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 53549131709     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008318499     Document Type: Review

References (24)

1. Projan SJ, Shlaes DM Antibacterial drug discovery: is it all downhill from here ? Clin Microbiol Infect. 2004 ; 10 (suppl 4). 18-22.
2. Spellberg B., Powers JH, Brass EP, Miller LG, Edwards JE Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004 ; 38: 1279-1286.
3. Projan SJ Why is big pharma getting out of antibacterial drug discovery ? Curr Opin Microbiol. 2003 ; 6: 427-430.
4. DiMassa JA, Hansen RW, Grabowski HG The price of innovation: new estimates of drug development costs. J Health Econ. 2003 ; 22: 151-185.
5. Powers JH Development of drugs for antimicrobial-resistant pathogens. Curr Opin Infect Dis. 2003 ; 16: 547-551.
6. Blaser MJ, Bartlett JG. Letter to FDA commissioner Andrews C. von Eschenbach, MD.: Infectious Diseases Society of America, 2006. Available at: http://www. idsociety.org/WorkArea/downloadasset.aspx?id=3384. Accessed February 24, 2008.
7. Boucher HW Open public forum. In: FDA Anti-Infective Drugs Advisory Committee: Joint with Drug Safety and Risk Management Advisory Committee. Silver Spring, MD. Available at http://idsociety.org/Content.aspx?id=7048. Accessed February 24, 2008.
8. Magill-Lewis J. Wanted: superdrugs. Drug Topics. 2007 ; 42-46.
9. ISDA Web site. Available at: http://www.idsociety.org/Content/ ContentGroups/IDSANews. Accessed February 24, 2008.
10. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Alexandria, VA: Infectious Diseases Society of America, 2004. Available at: http://www.fda.gov/ohrms/ dockets/DOCKETS/04s0233/04s-0233-c000005-03-IDSA-vol1.pdf. Accessed February 24, 2008.
11. Nelson R. Antibiotic development pipeline runs dry. Lancet. 2003 ; 362: 1726-27.
12. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007 ; 44: 159-177.
13. Rapp RP Fluoroquinolone positioning in hospital antimicrobial stewardship programs. US Pharm. 2007 ; 32HS10 - HS17.
14. Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am. 1995 ; 9: 497-530.
15. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med. 1996 ; 335: 1445-1453.
16. Kunin CM Resistance to antimicrobial drugs: a worldwide calamity. Ann Intern Med. 1993 ; 118: 557-561.
17. Reed SD, Laxminarayan R., Black DJ, Sullivan SD Economic issues and antibiotic resistance in the community. Ann Pharmacother. 2002 ; 36: 148-154.
18. Aiello AE, King NB, Foxman B. Ethical conflicts in public health research and practice: antimicrobial resistance and the ethics of drug development. Am J Public Health. 2006 ; 96: 1910-1914.
19. Talbot GH, Bradley J., Edwards JE, Gilbert D., Scheld M., Bartlett JG Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006 ; 42: 657-668.
20. Hagerman JK, Knechtel SA, Klepser ME Doripenem: a new extended-spectrum carbapenem antibiotic. Formulary. 2007 ; 42: 676-688.
21. Gaynes R., Edward JR Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005 ; 41: 848-854.
22. Biedenbach DJ, Moet GJ, Jones RN Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis. 2004 ; 50: 59-69.
23. Spellberg B., Guidos R., Gilbert D., et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the infectious diseases society of America. Clin Infect Dis. 2008 ; 46: 155-164.
24. Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control. Antimicrobial resistance: A Growing Threat to Public Health. Atlanta: Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control ; 2002.